The distinction matters enormously because each phenomenon requires a different reset strategy
"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine , 2025 (ATTAIN-1 trial) Eli Lilly press release: ATTAIN-2 Phase 3 topline results
Lately, more patients are asking about weight management either because their antipsychotic medications caused weight gain, or theyve heard about GLP-1 drugs like Ozempic and Wegovy and want to know if you can help
Clinical Evidence: No IGF-1 Changes Human clinical trials measured serum IGF-1 levels at baseline and throughout treatment with AOD-9604 at various doses
L- antineoplastic and immunomodulating agents This group targets neoplastic and immunological conditions, including antineoplastics (L01), endocrine therapy (L02), immunostimulants (L03), and immunosuppressants (L04)